<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254174</url>
  </required_header>
  <id_info>
    <org_study_id>1184.11</org_study_id>
    <nct_id>NCT02254174</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers</brief_title>
  <official_title>A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler®2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®], a Single Dose of 50μg Salmeterol (Serevent® Diskus®) and a Single Dose of 18 μg Tiotropium (Spiriva® HandiHaler®) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Assessment of the relative bioavailability of a fixed dose combination of tiotropium and
      salmeterol compared to a free dose combination of the marketed products of tiotropium and
      salmeterol (Spiriva® and Serevent® Diskus®).

      Assessment of the relative bioavailability of a fixed dose combination of tiotropium and
      salmeterol compared to tiotropium and salmeterol administered as individual mono substances
      from the marketed products.

      Assessment of safety and tolerability of the fixed combination of tiotropium and salmeterol
      in a PE (Polyethylene) capsule administered via the HandiHaler® 2
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of salmeterol in blood plasma over the time interval from 0 extrapolated to infinity);</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of salmeterol in blood plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ae0-8 (urinary excretion of tiotropium over an 8 hour interval)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of tiotropium in blood plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of tiotropium in blood plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt1-t2 (area under the concentration time curve in plasma over the time interval t1 to t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½ (terminal half-life of in plasma)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTih (mean residence time in the body after inhalational administration)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of in the plasma after extravascular administration)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)</measure>
    <time_frame>Up to 8 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet1-t2 (amount of analyte that is eliminated in urine from the time point t1 to time point t2</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)</measure>
    <time_frame>up to 8 hours after inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in physical examination</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in 12-lead ECG</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability assessed by investigator on a 4-point scale</measure>
    <time_frame>up to 90 days after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Salmeterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Serevent® Diskus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium/Salmeterol</intervention_name>
    <description>Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®</description>
    <arm_group_label>Tiotropium/Salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serevent® Diskus®</intervention_name>
    <arm_group_label>Serevent® Diskus®</arm_group_label>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva®</intervention_name>
    <arm_group_label>Spiriva®</arm_group_label>
    <arm_group_label>Spiriva® and Serevent® Diskus®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male based upon a complete medical history, including the physical
             examination, regarding vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG
             (electrocardiogram) measurement, and clinical laboratory tests. There is no finding
             deviating from normal and of clinical relevance.

             There is no evidence of a clinically relevant concomitant disease

          2. Age ≥21 and ≤50 years

          3. BMI ≥18.5 and &lt;30 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP (Good Clinical Practice) and the local legislation

        Exclusion Criteria:

          1. Any finding of the medical examination (including BP, PR, and ECG measurements)
             deviating from normal and of clinical relevance

          2. Evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its
             excipients) as judged clinically relevant by the investigator

          8. Intake of drugs with a long half-life (&gt;24 hours) within at least 1 month or less than
             10 half-lives of the respective drug prior to randomisation

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to enrolment in the
             study or during the study

         10. Participation in another trial with an investigational drug within 2 months prior to
             randomisation

         11. Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day)

         12. Inability to refrain from smoking on trial days as judged by the investigator

         13. Alcohol abuse (more than 40 g alcohol a day)

         14. Drug abuse

         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during
             the trial)

         16. Excessive physical activities within 1 week prior to randomisation or during the trial

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of the study centre

             The following exclusion criteria are specific for this study due to the known class
             side effect profile of ß2-mimetics:

         19. Asthma or history of pulmonary hyperreactivity

         20. Hyperthyrosis

         21. Allergic rhinitis in need of treatment

         22. Clinically relevant cardiac arrhythmia

         23. Paroxysmal tachycardia (&gt;100 beats per minute)

             The following exclusion criteria are specific for this study due to the known class
             side effect profile of tiotropium:

         24. Hypersensitivity to tiotropium and/or related drugs of this class
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

